MZT2A

Across TCGA pan-cancer cohorts, MZT2A mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MZT2A data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MZT2A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MZT2A expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where MZT2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.844	0.275	.010	24	view →
HNSC	OS	Quartile	IV	0.457	0.905	.027	12	view →
LSCC	OS	Tertile	II,III,IV	0.886	0.436	.002	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MZT2A–PDAC (DFS)

Open the PDAC breakdown →